Aspirin increases mitochondrial fatty acid oxidation

Radha Uppala, Brianne Dudiak, Megan Beck, Sivakama S. Bharathi, Yuxun Zhang, Donna B. Stolz, Eric S. Goetzman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The metabolic effects of salicylates are poorly understood. This study investigated the effects of aspirin on fatty acid oxidation. Aspirin increased mitochondrial long-chain fatty acid oxidation, but inhibited peroxisomal fatty acid oxidation, in two different cell lines. Aspirin increased mitochondrial protein acetylation and was found to be a stronger acetylating agent in vitro than acetyl-CoA. However, aspirin-induced acetylation did not alter the activity of fatty acid oxidation proteins, and knocking out the mitochondrial deacetylase SIRT3 did not affect the induction of long-chain fatty acid oxidation by aspirin. Aspirin did not change oxidation of medium-chain fatty acids, which can freely traverse the mitochondrial membrane. Together, these data indicate that aspirin does not directly alter mitochondrial matrix fatty acid oxidation enzymes, but most likely exerts its effects at the level of long-chain fatty acid transport into mitochondria. The drive on mitochondrial fatty acid oxidation may be a compensatory response to altered mitochondrial morphology and inhibited electron transport chain function, both of which were observed after 24 h incubation of cells with aspirin. These studies provide insight into the pathophysiology of Reye Syndrome, which is known to be triggered by aspirin ingestion in patients with fatty acid oxidation disorders.

Original languageEnglish (US)
Pages (from-to)346-351
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume482
Issue number2
DOIs
StatePublished - Jan 8 2017

Fingerprint

Aspirin
Fatty Acids
Oxidation
Acetylation
Cells
Reye Syndrome
Acetyl Coenzyme A
Mitochondria
Salicylates
Mitochondrial Proteins
Mitochondrial Membranes
Electron Transport
Thermodynamic properties
Eating
Membranes
Cell Line
Enzymes

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Uppala, R., Dudiak, B., Beck, M., Bharathi, S. S., Zhang, Y., Stolz, D. B., & Goetzman, E. S. (2017). Aspirin increases mitochondrial fatty acid oxidation. Biochemical and Biophysical Research Communications, 482(2), 346-351. https://doi.org/10.1016/j.bbrc.2016.11.066

Aspirin increases mitochondrial fatty acid oxidation. / Uppala, Radha; Dudiak, Brianne; Beck, Megan; Bharathi, Sivakama S.; Zhang, Yuxun; Stolz, Donna B.; Goetzman, Eric S.

In: Biochemical and Biophysical Research Communications, Vol. 482, No. 2, 08.01.2017, p. 346-351.

Research output: Contribution to journalArticle

Uppala, R, Dudiak, B, Beck, M, Bharathi, SS, Zhang, Y, Stolz, DB & Goetzman, ES 2017, 'Aspirin increases mitochondrial fatty acid oxidation', Biochemical and Biophysical Research Communications, vol. 482, no. 2, pp. 346-351. https://doi.org/10.1016/j.bbrc.2016.11.066
Uppala, Radha ; Dudiak, Brianne ; Beck, Megan ; Bharathi, Sivakama S. ; Zhang, Yuxun ; Stolz, Donna B. ; Goetzman, Eric S. / Aspirin increases mitochondrial fatty acid oxidation. In: Biochemical and Biophysical Research Communications. 2017 ; Vol. 482, No. 2. pp. 346-351.
@article{f464809d27da4e759d90e020e53bb137,
title = "Aspirin increases mitochondrial fatty acid oxidation",
abstract = "The metabolic effects of salicylates are poorly understood. This study investigated the effects of aspirin on fatty acid oxidation. Aspirin increased mitochondrial long-chain fatty acid oxidation, but inhibited peroxisomal fatty acid oxidation, in two different cell lines. Aspirin increased mitochondrial protein acetylation and was found to be a stronger acetylating agent in vitro than acetyl-CoA. However, aspirin-induced acetylation did not alter the activity of fatty acid oxidation proteins, and knocking out the mitochondrial deacetylase SIRT3 did not affect the induction of long-chain fatty acid oxidation by aspirin. Aspirin did not change oxidation of medium-chain fatty acids, which can freely traverse the mitochondrial membrane. Together, these data indicate that aspirin does not directly alter mitochondrial matrix fatty acid oxidation enzymes, but most likely exerts its effects at the level of long-chain fatty acid transport into mitochondria. The drive on mitochondrial fatty acid oxidation may be a compensatory response to altered mitochondrial morphology and inhibited electron transport chain function, both of which were observed after 24 h incubation of cells with aspirin. These studies provide insight into the pathophysiology of Reye Syndrome, which is known to be triggered by aspirin ingestion in patients with fatty acid oxidation disorders.",
author = "Radha Uppala and Brianne Dudiak and Megan Beck and Bharathi, {Sivakama S.} and Yuxun Zhang and Stolz, {Donna B.} and Goetzman, {Eric S.}",
year = "2017",
month = "1",
day = "8",
doi = "10.1016/j.bbrc.2016.11.066",
language = "English (US)",
volume = "482",
pages = "346--351",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Aspirin increases mitochondrial fatty acid oxidation

AU - Uppala, Radha

AU - Dudiak, Brianne

AU - Beck, Megan

AU - Bharathi, Sivakama S.

AU - Zhang, Yuxun

AU - Stolz, Donna B.

AU - Goetzman, Eric S.

PY - 2017/1/8

Y1 - 2017/1/8

N2 - The metabolic effects of salicylates are poorly understood. This study investigated the effects of aspirin on fatty acid oxidation. Aspirin increased mitochondrial long-chain fatty acid oxidation, but inhibited peroxisomal fatty acid oxidation, in two different cell lines. Aspirin increased mitochondrial protein acetylation and was found to be a stronger acetylating agent in vitro than acetyl-CoA. However, aspirin-induced acetylation did not alter the activity of fatty acid oxidation proteins, and knocking out the mitochondrial deacetylase SIRT3 did not affect the induction of long-chain fatty acid oxidation by aspirin. Aspirin did not change oxidation of medium-chain fatty acids, which can freely traverse the mitochondrial membrane. Together, these data indicate that aspirin does not directly alter mitochondrial matrix fatty acid oxidation enzymes, but most likely exerts its effects at the level of long-chain fatty acid transport into mitochondria. The drive on mitochondrial fatty acid oxidation may be a compensatory response to altered mitochondrial morphology and inhibited electron transport chain function, both of which were observed after 24 h incubation of cells with aspirin. These studies provide insight into the pathophysiology of Reye Syndrome, which is known to be triggered by aspirin ingestion in patients with fatty acid oxidation disorders.

AB - The metabolic effects of salicylates are poorly understood. This study investigated the effects of aspirin on fatty acid oxidation. Aspirin increased mitochondrial long-chain fatty acid oxidation, but inhibited peroxisomal fatty acid oxidation, in two different cell lines. Aspirin increased mitochondrial protein acetylation and was found to be a stronger acetylating agent in vitro than acetyl-CoA. However, aspirin-induced acetylation did not alter the activity of fatty acid oxidation proteins, and knocking out the mitochondrial deacetylase SIRT3 did not affect the induction of long-chain fatty acid oxidation by aspirin. Aspirin did not change oxidation of medium-chain fatty acids, which can freely traverse the mitochondrial membrane. Together, these data indicate that aspirin does not directly alter mitochondrial matrix fatty acid oxidation enzymes, but most likely exerts its effects at the level of long-chain fatty acid transport into mitochondria. The drive on mitochondrial fatty acid oxidation may be a compensatory response to altered mitochondrial morphology and inhibited electron transport chain function, both of which were observed after 24 h incubation of cells with aspirin. These studies provide insight into the pathophysiology of Reye Syndrome, which is known to be triggered by aspirin ingestion in patients with fatty acid oxidation disorders.

UR - http://www.scopus.com/inward/record.url?scp=85006943890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006943890&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2016.11.066

DO - 10.1016/j.bbrc.2016.11.066

M3 - Article

VL - 482

SP - 346

EP - 351

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -